| __timestamp | Johnson & Johnson | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21954000000 | 17986000 |
| Thursday, January 1, 2015 | 21203000000 | 32480000 |
| Friday, January 1, 2016 | 19945000000 | 68081000 |
| Sunday, January 1, 2017 | 21420000000 | 169906000 |
| Monday, January 1, 2018 | 22540000000 | 248932000 |
| Tuesday, January 1, 2019 | 22178000000 | 354100000 |
| Wednesday, January 1, 2020 | 22084000000 | 433300000 |
| Friday, January 1, 2021 | 20118000000 | 583300000 |
| Saturday, January 1, 2022 | 19046000000 | 752700000 |
| Sunday, January 1, 2023 | 20112000000 | 887600000 |
| Monday, January 1, 2024 | 21969000000 | 1007200000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Johnson & Johnson and Neurocrine Biosciences, Inc. have taken different paths in optimizing these costs.
From 2014 to 2023, Johnson & Johnson's SG&A expenses have shown a slight decline, with a 9% reduction from 2014 to 2022, before a slight uptick in 2023. This indicates a strategic focus on cost efficiency, despite their massive scale. In contrast, Neurocrine Biosciences, Inc. has seen a dramatic increase in SG&A expenses, rising nearly 50 times from 2014 to 2023. This surge reflects their aggressive expansion and investment in growth.
While Johnson & Johnson's approach highlights stability and efficiency, Neurocrine's strategy underscores growth and market penetration. Both strategies offer valuable insights into managing SG&A costs in the pharmaceutical industry.
Johnson & Johnson and Merck & Co., Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Amgen Inc.
Breaking Down SG&A Expenses: Johnson & Johnson vs Alnylam Pharmaceuticals, Inc.
Johnson & Johnson and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Exelixis, Inc.
Who Optimizes SG&A Costs Better? Johnson & Johnson or Jazz Pharmaceuticals plc
Breaking Down SG&A Expenses: Johnson & Johnson vs Alkermes plc
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioMarin Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Neurocrine Biosciences, Inc. and Jazz Pharmaceuticals plc
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Merus N.V.
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.